INNATE PHARMA SA-SPONS ADR (IPHA)
US45781K2042 - ADR
Taking everything into account, IPHA scores 3 out of 10 in our fundamental rating. IPHA was compared to 588 industry peers in the Biotechnology industry. IPHA may be in some trouble as it scores bad on both profitability and health. IPHA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IPHA has reported negative net income.
In the past year IPHA has reported a negative cash flow from operations.
IPHA had negative earnings in each of the past 5 years.
In the past 5 years IPHA reported 4 times negative operating cash flow.
1.2 Ratios
IPHA has a better Return On Assets (-4.11%) than 92.15% of its industry peers.
Looking at the Return On Equity, with a value of -14.59%, IPHA belongs to the top of the industry, outperforming 89.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.11% | ||
| ROE | -14.59% | ||
| ROIC | N/A |
ROA(3y)-17.27%
ROA(5y)-15.56%
ROE(3y)-57.01%
ROE(5y)-44.32%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IPHA has a better Gross Margin (94.50%) than 96.25% of its industry peers.
In the last couple of years the Gross Margin of IPHA has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for IPHA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.32%
GM growth 5Y-0.15%
2. Health
2.1 Basic Checks
IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IPHA has been increased compared to 1 year ago.
Compared to 5 years ago, IPHA has more shares outstanding
The debt/assets ratio for IPHA has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.93, we must say that IPHA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IPHA (-0.93) is comparable to the rest of the industry.
IPHA has a Debt/Equity ratio of 1.60. This is a high value indicating a heavy dependency on external financing.
IPHA's Debt to Equity ratio of 1.60 is on the low side compared to the rest of the industry. IPHA is outperformed by 81.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.6 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.93 |
ROIC/WACCN/A
WACC6.27%
2.3 Liquidity
IPHA has a Current Ratio of 3.73. This indicates that IPHA is financially healthy and has no problem in meeting its short term obligations.
IPHA has a Current ratio (3.73) which is in line with its industry peers.
IPHA has a Quick Ratio of 3.73. This indicates that IPHA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.73, IPHA is in line with its industry, outperforming 43.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.73 | ||
| Quick Ratio | 3.73 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 87.13% over the past year.
IPHA shows a small growth in Revenue. In the last year, the Revenue has grown by 4.68%.
Measured over the past years, IPHA shows a decrease in Revenue. The Revenue has been decreasing by -8.27% on average per year.
EPS 1Y (TTM)87.13%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q85.76%
Revenue 1Y (TTM)4.68%
Revenue growth 3Y-2.59%
Revenue growth 5Y-8.27%
Revenue growth Q2Q99.27%
3.2 Future
The Earnings Per Share is expected to grow by 45.36% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 31.71% on average over the next years. This is a very strong growth
EPS Next Y28.86%
EPS Next 2Y42.31%
EPS Next 3Y45.36%
EPS Next 5YN/A
Revenue Next Year-18.68%
Revenue Next 2Y30.28%
Revenue Next 3Y42.23%
Revenue Next 5Y31.71%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IPHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPHA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IPHA's earnings are expected to grow with 45.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.31%
EPS Next 3Y45.36%
5. Dividend
5.1 Amount
IPHA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INNATE PHARMA SA-SPONS ADR
NASDAQ:IPHA (5/3/2024, 7:00:02 PM)
2.5454
+0.12 (+4.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap205.78M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.11% | ||
| ROE | -14.59% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.5% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.6 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.73 | ||
| Quick Ratio | 3.73 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)87.13%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y28.86%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)4.68%
Revenue growth 3Y-2.59%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y